再発および治療抵抗性非ホジキンリンパ腫に対するCis-dichlorodiammineplatinumを中心とした併用療法の効果

塚崎 邦弘; 池田 柊一; 樅田 三郎; 長井 一浩; 村田 健; 徳永 清治; 河野 友子; 糸山 貴浩; 鳥谷 和洋; 栗山 一孝; 朝長 万左男; 市丸 道人

doi:10.11406/rinketsu.29.699

Effect of Combination Chemotherapy with Cis-dichlorodiammineplatinum on Relapsed or Therapy-resistant Non-Hodgkin's Lymphoma

Kunihiro TSUKASAKI, Shu-ichi IKEDA, Saburo MOMITA, Kazuhiro NAGAI, Ken MURATA, Seiji TOKUNAGA, Tomoko KOHNO, Takahiro ITOYAMA, Kazuhiro TORIYA, Kazutaka KURIYAMA, Masao TOMONAGA, Michito ICHIMARU

Author information

Kunihiro TSUKASAKI
Department of Hematology, Atomic Disease Institute, Nagasaki University School of Medicine
Shu-ichi IKEDA
Department of Hematology, Atomic Disease Institute, Nagasaki University School of Medicine
Saburo MOMITA
Department of Hematology, Atomic Disease Institute, Nagasaki University School of Medicine
Kazuhiro NAGAI
Department of Hematology, Atomic Disease Institute, Nagasaki University School of Medicine
Ken MURATA
Department of Hematology, Atomic Disease Institute, Nagasaki University School of Medicine
Seiji TOKUNAGA
Department of Hematology, Atomic Disease Institute, Nagasaki University School of Medicine
Tomoko KOHNO
Department of Hematology, Atomic Disease Institute, Nagasaki University School of Medicine
Takahiro ITOYAMA
Department of Hematology, Atomic Disease Institute, Nagasaki University School of Medicine
Kazuhiro TORIYA
Department of Hematology, Atomic Disease Institute, Nagasaki University School of Medicine
Kazutaka KURIYAMA
Department of Hematology, Atomic Disease Institute, Nagasaki University School of Medicine
Masao TOMONAGA
Department of Hematology, Atomic Disease Institute, Nagasaki University School of Medicine
Michito ICHIMARU
Department of Hematology, Atomic Disease Institute, Nagasaki University School of Medicine

Keywords: malignant lymphoma, non-Hodgkin's lymphoma, cis-dichlorodiammineplatinum, salvage therapy

JOURNAL RESTRICTED ACCESS

1988 Volume 29 Issue 5 Pages 699-704

DOI https://doi.org/10.11406/rinketsu.29.699

Details

Abstract

Twelve patients with non-Hogikin's lymphoma (NHL) unresponsive to the first line combination chemotherapy were treated with combination therapy with cis-dichlorodiammineplatinum (CDDP). Ten patients were evaluable for response. There were four complete and five partial responses. The durations of complete responses were 2-12 months (mean 6 months). Toxicity included nausea and vomiting in 100% of patients, myelosuppression in 75% and renal impairment in 67%, but all were reversible. This regimen appears useful as a salvage therapy for patients refractory to standard regimens.

Corresponding author

Register with J-STAGE for free!